Form 4: Mineralys Therapeutics CFO Sells Shares Under Pre-Arranged 10b5-1 Plan

Mineralys Therapeutics' CFO and Secretary, Adam Scott Levy, sold a total of 73,678 shares of common stock across four transactions in late July 2025, executed under a Rule 10b5-1 trading plan.

Summary

• Adam Scott Levy, the Chief Financial Officer and Secretary of Mineralys Therapeutics, Inc. (MLYS), reported multiple sales of common stock.
• On July 28, 2025, 12,946 shares were sold at a weighted-average price of $14.0432, leaving 193,666 shares beneficially owned.
• On July 29, 2025, 807 shares were sold at a weighted-average price of $14.0048, resulting in 192,859 shares beneficially owned.
• On July 30, 2025, two separate transactions occurred: 51,500 shares were sold at a weighted-average price of $14.7023, and 8,425 shares were sold at a weighted-average price of $15.0983.
• Following all reported transactions, Adam Scott Levy beneficially owns 132,934 shares of common stock.
• The sales were conducted pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly negative. While insider selling can be a negative signal, the fact that these transactions were conducted under a pre-arranged Rule 10b5-1 plan significantly mitigates the negative interpretation, suggesting routine financial planning rather than a reaction to adverse company developments.

Positives

• The reported sales were executed under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not based on new, non-public information, which can mitigate negative market interpretations of insider selling.

Negatives

• The transactions represent a reduction in direct equity exposure by a key executive, which can sometimes be perceived negatively by investors, regardless of the underlying reason.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general market perception associated with insider selling, even when pre-planned.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is an insider transaction report specific to Mineralys Therapeutics and its CFO. It does not provide information related to broader industry trends or competitor activities.

Comparison to Industry Standards

• Not applicable for an insider transaction report, as it does not contain financial performance metrics or operational results that can be benchmarked against industry standards or comparable companies.

Stakeholder Impact

• Shareholders may observe a reduction in direct insider ownership, but the pre-arranged nature of the sales (10b5-1 plan) suggests a lower risk of negative implications for company fundamentals.

Key Dates

Recommendation

The insider sales by the CFO, while reducing his direct equity exposure, were conducted under a pre-arranged Rule 10b5-1 trading plan. This suggests the transactions were for personal financial planning rather than a reaction to new, negative company-specific information, thus not warranting a change from a 'hold' position based solely on this filing.

Keywords

Mineralys Therapeutics, MLYS, Form 4, Insider Trading, Stock Sale, Adam Scott Levy, CFO, Beneficial Ownership, SEC Filing, 10b5-1 Plan